Falling sales to hospitals are forcing Cardinal Health to cut 1,300 jobs from the clinical and medical products units that it plans to float under the CareFusion banner later this year.
Cardinal Health’s announcement that it is considering spinning off some of its divisions has provoked fevered speculation among industry analysts and media observers alike.
The contract manufacturing business that Cardinal Health sold
earlier this year has just been launched as an independent
operating company rebranded as Catalent Pharma Solutions.
Cardinal Health, the leading contract manufacturer for the
pharmaceutical industry, has announced its plans to sell its drug
manufacturing and packaging unit in order to focus on its
health-care business.
Bentley Pharmaceuticals has announced it will use the North
Carolina facilities of US-based services provider Cardinal Health
for the scale-up and manufacture of the clinical supplies of its
new intranasal insulin product.
Cardinal Health reported a mixed bag of results in its fourth
quarter, with revenues rising well on the back of rising demand for
its pharmaceutical distribution services, although operating profit
fell 9 per cent, in line with forecasts,...
Pharmaceutical distribution and technology company Cardinal Health
reported a slide in profits in the second quarter of the year, as
an internal investigation into the company's accounting practices
claimed additional executive...
Cardinal Health reported its long-delayed fourth-quarter financial
results yesterday, revealing a hike in profit and revenues for the
three months to end June, but lowered guidance for the first half
of this fiscal year.
US-based healthcare conglomerate Cardinal Health has stepped up its
presence in the European market with the appointment of a new
management team for the region based in the UK.
Cardinal Health has said that it will not be proceeding with a $100
million (€78m) information technology and manufacturing facility in
Longford, Ireland.
Healthcare giant Cardinal Health reported revenues up 11 per cent
to $14.1 billion (€11.2bn) in the fourth-quarter of 2003, as a
strong performance in its pharmaceutical manufacturing services,
pharmacy automation and medical product...